Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Careful, That News May Be Hot!

Related Content

Second Circuit Sees Eye to Eye With Warby Parker in Trademark Google Ads Dispute

What’s Next for AI? Six Areas to Watch in 2024

U.S. Supreme Court Holds Willfulness Not Needed for Recovery of Trademark Profits

In Role Reversal, Celebrities Defend Against Paparazzi Suits

SpongeBob and the 'Oh, Please!' Standard of Trademark Foolishness

Federal Circuit Will Not Review PTAB’s Use of the Broadest Reasonable Interpretation Claim Construction Standard in Post-Grant Proceedings

IP Advisor

Federal Circuit to Consider Whether Delay in Filing Suit Can Bar Damages or Injunctive Relief in Patent Cases

Best Lawyers Best Law Firms 2025 Names Goodwin Biotechnology and Life Sciences Law Firm of the Year for the Eighth Time and Recognizes 55 Practice Areas

Goodwin Advises HLTH in its Acquisition by Hyve

Sedona Conference WG9/10 Annual Meeting 2024

Human Immunology Biosciences to be Acquired by Biogen For $1.15 Billion Upfront and up to $650 Million in Potential Milestone Payments

IP Leadership Executive North America 2024

2024 Sedona Conference on Global Intellectual Property Litigation

WTR 1000 2024 Names Goodwin a Leader in Trademark Law

Goodwin CLE Days 2024

Trademarks